We are live on ! Find out more
OKUR

OnKure Therapeutics
OKUR

58 hedge funds and large institutions have $208M invested in OnKure Therapeutics in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 4

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

23% more capital invested

Capital invested by funds: $169M → $208M (+$39.4M)

12% more funds holding

Funds holding: 52 → 58 (+6)

0.3% more ownership

Funds ownership: 7.79% → 8.09% (+0.3%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

60% less call options, than puts

Call options by funds: $8K | Put options by funds: $20K

Holders
58
Holders Change
+6
Holders Change %
+11.54%
% of All Funds
0.92%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
10
Increased
22
Reduced
13
Closed
4
Calls
$8K
Puts
$20K
Net Calls
-$12K
Net Calls Change
-$12K

Top Buyers

Rank Fund Capital Flow
1
Invesco
Invesco
Georgia
+$3.06M
2
EAM
Eventide Asset Management
Massachusetts
+$2.23M
3
WP
Woodline Partners
California
+$1.38M
4
BlackRock
BlackRock
New York
+$1.1M
5
Franklin Resources
Franklin Resources
California
+$1.01M

Top Sellers

Rank Fund Capital Flow
1
ECM
ExodusPoint Capital Management
New York
-$1.2M
2
JGC
J. Goldman & Co
New York
-$1.02M
3
IC
Ikarian Capital
Texas
-$1.02M
4
OCA
Octagon Capital Advisors
New York
-$603K
5
Walleye Capital
Walleye Capital
New York
-$325K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMC
1
NEA Management Company
Maryland
$36.4M – – –
NHAS
2
Novo Holdings A/S
Denmark
$25.3M – – –
CG
3
Carlyle Group
District of Columbia
$20.5M – – –
RVM
4
RiverVest Venture Management
Missouri
$19.3M – – –
OCA
5
Octagon Capital Advisors
New York
$17.4M -$603K -8,872 -4%
EAM
6
Eventide Asset Management
Massachusetts
$15.8M +$2.23M +32,814 +19%
Franklin Resources
7
Franklin Resources
California
$11.4M +$1.01M +14,821 +11%
GPP
8
Great Point Partners
Connecticut
$8.89M +$570K +8,374 +8%
RSCM
9
Rock Springs Capital Management
Maryland
$8.71M – – –
Vanguard Group
10
Vanguard Group
Pennsylvania
$7.43M +$118K +1,730 +2%
ACM
11
Aisling Capital Management
New York
$6.74M – – –
BlackRock
12
BlackRock
New York
$4.71M +$1.1M +16,189 +35%
WP
13
Woodline Partners
California
$3.43M +$1.38M +20,265 +82%
Invesco
14
Invesco
Georgia
$3.42M +$3.06M +44,936 New
ECM
15
ExodusPoint Capital Management
New York
$2.89M -$1.2M -17,634 -32%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$2.52M +$246K +3,617 +12%
FLAM
17
First Light Asset Management
Minnesota
$2.07M +$152K +2,232 +9%
State Street
18
State Street
Massachusetts
$1.66M +$43.7K +642 +3%
JGC
19
J. Goldman & Co
New York
$1.18M -$1.02M -15,066 -49%
MCM
20
MAI Capital Management
Ohio
$942K +$389K +5,723 +86%
Millennium Management
21
Millennium Management
New York
$934K +$834K +12,269 New
Northern Trust
22
Northern Trust
Illinois
$916K +$137K +2,018 +20%
BCM
23
Bridgeway Capital Management
Texas
$696K +$230K +3,388 +59%
Barclays
24
Barclays
United Kingdom
$595K +$28.9K +425 +6%
Adage Capital Partners
25
Adage Capital Partners
Massachusetts
$495K +$442K +6,500 New
1
2 3

OKUR Hedge Fund Activity: Q3 2023 in Review

58 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in OnKure Therapeutics (OKUR) for Q3 2023, worth a combined $208M — up 23% from $169M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new OKUR positions and 4 closed out — a net gain of 6 holders — while 22 added to existing stakes and 13 trimmed.

The largest buyer was Invesco, opening a new position worth an estimated $3.06M. The largest seller was ExodusPoint Capital Management, cutting an estimated $1.2M.

  • 58 institutional investors held OnKure Therapeutics (OKUR) as of Q3 2023, up from 52 in Q2 2023.
  • Funds reported $208M of OnKure Therapeutics stock for Q3 2023, up 23% quarter-over-quarter.
  • 10 funds opened new OnKure Therapeutics positions in Q3 2023 and 4 closed out, a net change of +6 holders.
  • The largest OnKure Therapeutics buyer in Q3 2023 was Invesco, an estimated $3.06M added.
  • The largest OnKure Therapeutics seller in Q3 2023 was ExodusPoint Capital Management, an estimated $1.2M sold.

Based on aggregated 13F filings for Q3 2023.